Spes Immunotherapeutics Revenue

Biotechnology Research • CoSymbio Lab, Barcelona, Spain • 1-10 Employees

Spes Immunotherapeutics revenue & valuation

Annual revenue	$171,110
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$547,552
Total funding	No funding

Key Contact at Spes Immunotherapeutics

Ricky Tirtakusuma

Co-Founder

Company overview

Headquarters	CoSymbio Lab, Barcelona, Spain
NAICS	541714
Founded	2025
Employees	1-10

About Spes Immunotherapeutics

Spes Immunotherapeutics is a biotech startup dedicated to revolutionizing cancer care through cutting-edge precision immunotherapies. Founded upon groundbreaking research in oncology and immunology, we are committed to developing highly targeted therapies aimed at providing lasting solutions to some of the most aggressive cancers. Headquartered in Barcelona, a dynamic hub for biotechnology innovation, our multidisciplinary team combines deep scientific expertise and strategic vision to rapidly translate promising science into transformative clinical outcomes. At Spes, we envision a future where cancer relapse is no longer inevitable, but preventable—enabling patients to live healthier, fuller lives. Join us as we advance innovative therapies designed to redefine standards of care in oncology.

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Founder/Owner

Employees by Department

Spes Immunotherapeutics has 1 employees across 1 departments.

Departments

Number of employees

Funding Data

Spes Immunotherapeutics has never raised funding before.

Frequently asked questions

Spes Immunotherapeutics is located in CoSymbio Lab, Barcelona, ES.

Spes Immunotherapeutics generates an estimated annual revenue of $171,110. This revenue figure reflects the company's market position and business performance in its industry.

Spes Immunotherapeutics has an estimated valuation of $547,552. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Spes Immunotherapeutics was founded in 2025, making it 1 years old. The company has established itself as a significant player in its industry over this time.

Spes Immunotherapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contact at Spes Immunotherapeutics

Ricky Tirtakusuma

Co-Founder

4.8

40,000 users